AbbVie makes psychedelic play with $2bn Gilgamesh collaboration
The two companies will develop neuroplastogens for psychiatric disorders as psychedelic market activity ramps up.
The two companies will develop neuroplastogens for psychiatric disorders as psychedelic market activity ramps up.
What's Your Reaction?
